This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Power calculations were performed in the preliminary phase of the study. Assuming a 90% cure rate and a 10% difference in the cure rate between procedures, a sample of 197 patients in each group was required to detect a statistically significant difference in the main outcome measure with 80% power (262 patients to achieve 90% power). A sample of 344 women, who were recruited from outpatient clinics once surgery had been selected for their stress incontinence, was enrolled in the study. There were 175 women (median age: 50 years; interquartile range: 42 -56) in the TFVT group and 169 women (median age: 50 years; interquartile range: 45 -59) in the COLP group. Only 170 women in the TFVT group and 146 in the COLP group received the treatment. The remaining patients withdrew consent, declined surgery, or were ineligible for the trial.
Study design
This was a multicentre, prospective, randomised clinical trial, which was carried out in 14 centres (both university teaching hospitals and district general hospitals). Blinding was not possible due to the apparent differences in the procedures performed. The patients were randomised using a telephone system and a computer-generated procedure. The women were grouped into blocks of four and six participants. The length of follow-up was 6 months. The patients were initially contacted 6 weeks after surgery through a postal questionnaire and then after 6 months for clinical examination, symptom review and urodynamic tests. Some loss to follow-up occurred before the end of the follow-up period. The final data were available for 152 women in the TFVT group and 127 patients in the COLP group.
Analysis of effectiveness
The basis for the clinical study was intention to treat. The primary outcome measure was the cure rate, based on a negative stress test on urodynamic testing combined with a negative 1-hour pad test. The secondary health outcomes were subjective cure of incontinence and the development of voiding problems, urge symptoms, and vaginal prolapse. These were estimated using the SF-36 questionnaire (incontinence) and the Bristol female lower urinary tract symptoms questionnaire (voiding, urge and prolapse), respectively. The study groups appear to have been comparable at baseline in terms of their age and clinical characteristics. Comparability was also observed between those who remained in and those who withdrew from the study.
Effectiveness results
The cure rate was 66% in the TFVT group and 57% in the COLP group, (p=0.099; 95% confidence interval, CI, for the difference: -4.7% -21.3%).
Improvements in most secondary outcomes were observed in both groups. There were no statistically significant differences.
After 6 months, TFVT patients experienced greater improvements than COLP women for some dimensions of the SF-36 scores (role emotional, energy/vitality, mental health and social functioning. However, the change in the overall index did not reach statistical significance.
Clinical conclusions
The two procedures were comparable in terms of cure rates and most clinical outcomes. However, the patients' perceptions of their own health improved in the TFVT group.
Discounting was not relevant since the costs per patient were incurred during 6 months. The unit costs and the quantities of resources used were presented separately and a breakdown of the cost items was provided. The health services included in the economic evaluation were ward 'hotel' services, theatre, anaesthetic room, recovery area, overheads, key consumables (TFVT and staple gun), outpatient and day-case visits, and general practitioner visits. Drug, treatment of complications, and staff expenses were included in each cost category reported above.
The cost/resource boundary of the UK NHS was adopted. Resource use was estimated from actual data, which were collected using case report forms completed by clinical staff on the same group of women as those enrolled in the effectiveness study. As in the analysis of the QALYs, missing data were excluded from the base-case analysis. The unit costs came from the British National Formulary, a survey of three UK hospitals, PSSRU, the Chartered Institute of Public Finance and Accountancy, and official doctors' remunerations. Value-added tax was included when appropriate. The costs were estimated using 1999 -2000 prices. The costs were updated to 1999 -2000 values by considering health service inflation.
Statistical analysis of costs
The skewed distribution of the resource use data was accounted for by using non-parametric bootstrap (based on 2.5 and 97.5 centiles). The costs were presented as mean (and median) values +/-standard distribution and interquartile ranges. The 95% CIs were also presented for differential costs.
Indirect Costs
The indirect costs were not included in the economic evaluation.
Currency
UK pounds sterling ().
Sensitivity analysis
To deal with incomplete cost and utility data, the missing values were imputed using a multivariate multiple imputation procedure and the analysis was carried out on the whole sample of women included in the effectiveness study. Another sensitivity analysis was performed to assess the impact of the length of hospital stay and cost of inpatient stay on the estimated cost-effectiveness ratio. It appears that a univariate analysis has been carried out.
Estimated benefits used in the economic analysis
The mean QALYs gained per patient were 0.397 (median 0.42; interquartile range: 0.35 -0.45) in the TFVT group and 0.387 (median 0.40; interquartile range: 0.35 -0.44) in the COLP group. The difference in QALY (TFVT minus COLP) was 0.010 (95% CI: -0.010 -0.030). When missing values were imputed and considered in the sample of patients, the difference in QALY was 0.012 (95% CI: -0.006 -0.029).
Cost results
The mean total costs per patient were 1,058 (+/-935) (95% CI: 839 -1,100) in the TFVT group and 1,301 (+/-1,195) (95% CI: 1,050 -1,449) in the COLP group. The difference in cost (TFVT minus COLP) was -243 (95% CI: -341 --201). When missing values were imputed, the difference in cost was -242 (95% CI: -340 --183).
Synthesis of costs and benefits
On the basis of the point estimates of costs and QALYs, TFVT dominated COLP, which was both more costly and less effective. However, some uncertainty exists in the point estimates, mainly on the QALY side. The acceptability curve, used to deal with the issue of uncertainty, suggested that the probability that TFVT was less costly than COLP was 100%. Also, that the probability of TFVT being more cost-effective was 94.6% when the decision-maker was willing to pay at least 30,000 per QALY.
The sensitivity analysis showed that TFVT was more likely to be cost-effective as long as the differential inpatient length of stay for women in the TFVT group was no more than one day higher than for those who underwent COLP. When missing data were imputed, similar conclusions were reached. Variations in the cost of inpatient stay had no impact on the base-case results.
